Work

Oral Mercaptopurine Adherence in Pediatric All: a Survey Study From the Dfci All Consortium

Year: 2020

Type: preprint

Abstract: Poor adherence to 6-mercaptopurine during acute lymphoblastic leukemia (ALL) therapy increases relapse risk. Clinically-significant non-adherence has been documented in up to 30% of children treated for ALL on Children’s Oncology Group trials. Whether non-adherence rates vary across regimens with different chemotherapy schedules and modes of administration is not known. In a cross-sectional survey study of N= 61 children treated on, or as per Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 11-001, 25% (95% CI 14 – 37%) of respondents self-reported non-adherence to 6MP, suggesting that the frequency of non-adherence may be similar across different Consortia regimens.

DOI: 10.22541/au.160322421.10925954/v1

Authors: Justine Kahn, Maneka Puligandla, Kristen Stevenson, Peter Cole, Jennifer Welch, Melissa Beauchemin, Elizabeth Gage-Bouchard, Lewis Silverman, Kara Kelly, Kira Bona

Institutions: Columbia University Irving Medical Center, Dana-Farber Cancer Institute, Rutgers, The State University of New Jersey, Hasbro Children's Hospital, Columbia University, Roswell Park Comprehensive Cancer Center

Language: English

Topic: Medication Adherence and Compliance

Subfield: Family Practice

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Funders: National Institutes of Health, Irving Medical Center, Columbia University, National Cancer Institute

Awards: G1288753112, G4779225333, Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer, G9000034383, G9000196512

OpenAlex ID: W3097376859

Cites: 9

Cited by:

Related to: 10